View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
August 12, 2009

European CRO Selects OmniComm To Provide eClinical Solutions

Study expected to last for 48 months

By CBR Staff Writer

OmniComm Systems has announced that it has been selected by a leading European Contract Research Organization (CRO), to provide eClinical solutions for a pivotal phase III study in rheumatoid arthritis (RA).

Phase III clinical studies serve to establish the safety and efficacy of investigational new drugs, and are the last step prior to review for approval by the regulatory authorities. This particular RA study is expected to last 48 months and enroll close to 300 patients in 20 sites located in Europe.

Stephen Johnson, COO of OmniComm, said: We are very excited to be working again with this CRO on this pivotal study. We appreciate their ongoing trust in us and will continue to deliver superior products and services to them. We are also very excited about our continued expansion into the European marketplace. We have recently opened up another office in the United Kingdom, OmniComm Ltd., which will allow us to broaden our service and support offering even further.

Content from our partners
Rethinking cloud: challenging assumptions, learning lessons
DTX Manchester welcomes leading tech talent from across the region and beyond
The hidden complexities of deploying AI in your business

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.